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Abstract
Background
Cord blood contains high number of hematopoietic cells that after birth disappear. In this
paper we have studied the functional properties of the umbilical cord blood progenitor cells
collected from term and preterm neonates to establish whether quantitative and/or qualita-
tive differences exist between the two groups.
Methods and Results
Our results indicate that the percentage of total CD34+ cells was significantly higher in pre-
term infants compared to full term: 0.61% (range 0.15–4.8) vs 0.3% (0.032–2.23) p =
0.0001 and in neonates <32 weeks of gestational age (GA) compared to those32 wks
GA: 0.95% (range 0.18–4.8) and 0.36% (0.15–3.2) respectively p = 0.0025. The majority of
CD34+ cells co-expressed CD71 antigen (p<0.05 preterm vs term) and grew in vitro large
BFU-E, mostly in the second generation. The subpopulations CD34+CD38- and CD34
+CD45- resulted more represented in preterm samples compared to term, conversely, Side
Population (SP) did not show any difference between the two group. The absolute number
of preterm colonies (CFCs/10microL) resulted higher compared to term (p = 0.004) and
these progenitors were able to grow until the third generation maintaining an higher propor-
tion of CD34+ cells (p = 0.0017). The number of colony also inversely correlated with the
gestational age (Pearson r = -0.3001 p<0.0168).
Conclusions
We found no differences in the isolation and expansion capacity of Endothelial Colony
Forming Cells (ECFCs) from cord blood of term and preterm neonates: both groups grew in
vitro large number of endothelial cells until the third generation and showed a transitional
phenotype between mesenchymal stem cells and endothelial progenitors (CD73, CD31,
PLOS ONE | DOI:10.1371/journal.pone.0138680 September 29, 2015 1 / 14
a11111
OPEN ACCESS
Citation: Podestà M, Bruschettini M, Cossu C,
Sabatini F, Dagnino M, Romantsik O, et al. (2015)
Preterm Cord Blood Contains a Higher Proportion of
Immature Hematopoietic Progenitors Compared to
Term Samples. PLoS ONE 10(9): e0138680.
doi:10.1371/journal.pone.0138680
Editor: Zoran Ivanovic, French Blood Institute,
FRANCE
Received: May 26, 2015
Accepted: September 1, 2015
Published: September 29, 2015
Copyright: © 2015 Podestà et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This study was founded by Ministero della
Salute Ricerca Corrente 5Xmille 2012-2013. The
funders had no role in study design, data collection
and analysis, decision to publish and preparation of
the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
CD34 and CD144)The presence, in the cord blood of preterm babies, of high number of
immature hematopoietic progenitors and endothelial/mesenchymal stem cells with high pro-
liferative potential makes this tissue an important source of cells for developing new cells
therapies.
Introduction
In mammals, the initial phase of blood production occurs in yolk sac (YS) and is termed primi-
tive haematopoiesis; during this phase, blood cells and large erythroid progenitors with mega-
karyocyte and macrophages potential can be detected, loosely associated with vascular
endothelial cells (the so-called blood islands) [1]. These cells are rapidly replaced by embryonic
definitive erythrocytes which are smaller than their primitive counterparts but larger than
adult erythrocytes [2]. In humans, until 30 days gestational age (GA), the area surrounding the
dorsal aorta, termed the Aorta-Gonad Mesonephros (AGM) region, consists in a matrix with
CD146+ vascular endothelial cells capable to generate Haematopoietic Stem Cells (HSCs) with
higher self-renewal capacity compared to UCB and adult BM HSCs[3,4,5]. The hematopoietic
activity in the AGM region precedes that in the embryonic liver, which is colonized around
week +7–8 of development and that in the placenta, which acquires HSC activity starting from
week +9 of development, long term after the emergence of HSCs in the AGM region [6]. By
week+11 well formed arterioles permit cell trafficking and migration and from week +16 hema-
topoiesis is organized within long bones with areas of fully calcified trabecular bones and areas
of dense hematopoiesis [7].
The relative contribution of each of the above sites to the final pool of adult Hematopoietic
Stem Cells (HSC) remains largely unknown and it is believed that none of these sites is accom-
panied by de novo HSC generation, rather, than these niches support the expansion of migrat-
ing HSCs capable of hematopoietic reconstitution, at least starting from AGM region [8].
HSCs may differ in their properties depending on their location (fetal liver, bone marrow,
placenta) and on the age of the fetus; thus, it is important to identify mechanisms that regulate
their cell function. The classical hierarchy diagram depicting progenitors arising from an “ideal”
HSC provides a simplified view of the hematopoietic system. HSCs may be described more
accurately as groups of cells with varying developmental potentials based on intrinsic properties
due to their own genetic program and inputs from the cellular niches in which they reside [9].
Human cord blood (UCB) is a reservoir of a relatively high number of stem cells (HSC,
EPC,HSC), with unique functional characteristics probably due to the fact that these cells are
neither completely fetal nor adult cells.Its therapeutic use has been proved since 1988, when
the first allogeneic HSC transplant was performed; currently, more than 160 public UCB banks
have been established worldwide and there are ~730 000 UCB units available for public use,
mainly for HSC transplant. In addition, an estimated 4.0 million UCB units have been stored
for private or family use as guarantee of future application in regenerative medicine and cellu-
lar therapies [10].Despite the extensive characterization of UCB progenitors cells, few studies
have examined the properties of preterm and early preterm cord blood cells. These studies
have demonstrated that preterm UCB shows a significantly higher concentration of haemato-
poietic progenitors with increased clonogenic capacity compared to term and an early cellular
differentiation, at least in vitro [11, 12, 13]. However, despite the higher proliferative potential,
preterm human HSCs demonstrate an impaired homing ability into the NOD/SCID mice,
probably due to a lower expression of adhesion molecules [14].
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Preterm birth is associated with high mortality rate and high risk of developing disability.
The number of long term complications like bronchopulmonary dysplasia (BPD), retinopathy
of prematurity and intracranial hemorrhages, diseases associated to tissue damage, are
inversely related to gestational age. Recent insights into pre-clinical studies have focused
mainly on potential forms of treatment for BPD, the chronic lung disease of prematurity [15–
17]. In fact, it has been demonstrated that the frequency of ECFCs is directly correlated with
the gestational age and that extremely preterm infants, who display lower numbers at birth,
have an increased risk of developing BPD due to lung vascular immaturity [18].In this contest,
cord blood-derived stem cells may be a suitable adjuvant therapy for indications in which
inflammation and tissue damage occurs.
In this paper, we have studied the functional properties of the umbilical cord blood cells col-
lected from term and preterm neonates in order to establish whether quantitative and qualita-
tive differences exist between the two groups. These cells may be a source of hematopoietic and
non-hematopoietic progenitors for immature newborns, to be used for prevent complications
related to inflammation, immune disregulation and organ fibrosis.
Materials and Methods
Samples
Cord blood was obtained from umbilical cord vessels of premature and full-term infants of
pregnant women immediately after delivery. All participants provide their written informed
consent to participate in this study.Exclusion criteria were positivity for HBV, HCV and HIV.
This study was approved by the Ethics Committee of the IRCCS Istituto G. Gaslini, Genoa
(N° 164 22th July 2013).The cord blood samples were transferred into the laboratory and ana-
lyzed within 12 hours from collection. The definitions of preterm and full term used herein are
those adopted by the World Health Organization:<37 weeks gestational age (GA) and37
weeks GA respectively; conversely, very preterm neonates are defined as having GA<32wks.
Immunophenotypic analysis, side population assay, ALDH activity, and
pluripotency gene expression
The enumeration of the hematopoietic progenitor cells (CD34+) was performed by FACS anal-
ysis as previously described [19]. After immunofluorescence staining, erythrocytes were lysed
with ammonium chloride lysis solution, acquired within one hour by flow cytometry (FACS-
CANTO II, BD Biosciences) and analyzed using FlowJo software (TreeStar Inc., Ashland, OR,
USA). CD34+ cells were gated according to the modified ISHAGE criteria [20].
Analysis of immature progenitors within CD34+ compartment was performed using antihu-
man antibodies: VioBlue-CD34 (MiltenyiBiotec), FITC- Lineage Cocktail 1 (lin 1; CD3, CD14,
CD16, CD19, CD20, CD56), APC-CD38 (BD) and PE-CD90 (BD Biosciences)[12]
Side population (SP) cells were identified in both preterm and term CB as previously
described [21]. Mononuclear cells were resuspended at 106 cells/mL in warmed staining buffer
[DMEM supplemented with 2% fetal calf serum (FCS)] and incubated with 5 μMDye Cycle
Violet (DCV; Molecular Probes Invitrogen Inc.,) for 30 min at 37°C. To set the gates for SP
cells, an aliquot of cells was pre-incubated with 50 μMVerapamil (Sigma-Aldrich) for 30 min
at 37°C before staining with DCV. At the end of the incubation, cells were labeled with anti-
CD34 (BD Biosciences), CD338 (ABCG-2; Miltenyi Biotechnology) and 7-AAD (EBioScience)
and subsequently detected on an LSRFortessa flow cytometer (BD Biosciences). Results werea-
nalyzed using FlowJo software according to the gating strategy previously described [22].
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Aldehyde dehydrogenase (ALDH) activity in HSC was evaluated by using Aldefluor reagent
(StemCell Technologies) according to the manufacturer’s instructions. Cells were resuspended
in aldefluor assay buffer and an appropriate amount of aldefluor substrate was added to 1x106
MNCs. Cells were incubated for 30 minutes at 37°C for conversion of substrate to a fluorescent
product. An aliquot of Aldefluor- stained cells were immediately treated with diethylamino-
benzaldehyde (DEAB), a specific ALDH inhibitor, to serve as negative control. Aldefluor- sub-
strate labeled cells were then costained with anti- CD34 VioBlue (Miltenyi Biotechnology) and
CD38 APC (Bd Biosciences) and subsequently analyzed by FACS.
To evaluate pluripotency gene expression, CD34- stained MNCs were fixed and permeabi-
lized with BD Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer’s instruc-
tions. Cells were stained for Nestin, OCT3/4 and Nanog with an PE-conjugated mAb(BD
Pharmigen, EBioScience, BD Pharmigen) or isotype controls for 20 minutes at 4°C and then
analyzed by flow cytometry.
Clonogenic assays
Methylcellulose-based semisolid assay was used to evaluate Colony Forming Cells (CFCs) [23].
All assays (first and secondary generation colonies) were performed using Methocult H4434
Classic (StemCellTM Technologies, Vancouver BC) which is a methyl-cellulose based medium
added with rhSCF, rhGM-CSF,rhIL-3 and rhEPO for the culture of human cells.
First generation: 5μl of whole Cord Blood (WCB) were added to 1 mL semisolid culture
medium and plated in duplicate on 24-wells plates. After 14 days of incubation in a humidified
atmosphere at 37°C and 5% CO2, colonies were evaluated for number and morphology in the
same dish using an inverted microscope.Second generation: colonies grown in first generation
were collected, pooled and dissociated using Dulbecco’s modified Eagle’s medium(DMEM,Life
Technologies). Nucleated cells (NC) were counted manually and 5x104NC were plated using
the same culture conditions of the first generation. The same procedure was performed for the
third generation culturing 105 NC.
The enumeration of CD 34+ cells was performed by FACS analysis on cells obtained from
colony pools(first and second generation).
CD34 positive cell enrichment and RNA isolation
UCB mononuclear cells (MNC) were isolated from fresh heparinized cord blood by density
gradient separation and enriched for CD34+ antigen by immune-selection method (Miltenyi
Biotech, Germany). Following two cycles on separate columns, CD34+cell purity was assessed
by flow cytometry: only samples ranging between 85% to 95% were selected for RNA
extraction.
Isolation of total RNA from CD34+ cells was performed with the RNeasyMicroKit (Qiagen
AG, Hilden, Germany). RNA obtained was reverse transcribed using the High Capacity RNA-
to-cDNA Kit according to the manufacturer’s instructions and performed on 2720 thermal
cycler (Applied Biosystems). RNA isolated from different samples (2–4) was pooled to obtain
the amount requested for gene profiling.
TaqMan Array Gene Profiling
TaqMan1 Gene Expression Assays have been designed using manufacturer’s validated bioin-
formatics pipeline (Applied Biosystems, CA, USA) and consisted in a selected list of target
genes (S1 Table) which were processed as described by the instructions. Quantitative real-time
PCR (qPCR) was performed with the ViiA™ 7 Real-Time PCR System (AppliedBiosystems).
Relative quantification was established by Comparative Ct method (2−ΔΔCt) with 18S ribosomal
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RNA as internal control and normalized to the expression of Human Reference Total RNA
(Stratagene). Analysis of the results was done using the Expression Suite Software V1.0.3 (Life
Technologist).
Endothelial Colony Forming Cell (ECFC)
ECFC cultures were performed by plating UCB-MNCs (5x106/well) on 6-wells culture dishes
coated with collagen (Sigma-Aldrich, Milan Italy) in endothelial cell growth medium EGM-2
Bullet Kit (Lonza-Euroclone) [24]. ECFCs are expressed as ECFCs frequency/107MNC. Endo-
thelial colonies were identify using a) morphological criteria; b) immunophenotypic analysis
(fluorescence microscopy and flow cytometry).
For immunofluorescence analysis, endothelial colonies were fixed with 4% paraformalde-
hyde, washed with phosphate-buffered saline (PBS) and then incubated with mouse anti-
human CD31 (DakoCytomation, Milan, Italy).Goat anti mouse-Alexa Fluor 488 (Molecular
Probes, Invitrogen S.R.L., Milan, Italy) conjugated antibodies was used as secondary antibodies
and4’,6’-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame,CA, USA) was
used for nuclear counterstaining. Both cell morphology and green fluorescence were then ana-
lyzed by inverted fluorescent microscope (Axio Vert. A1, Carl Zeiss S.p.A., Milan Italy)
Immunophenotypic characterization was performed on expanded ECFC at P2–P3. The fol-
lowing monoclonal antibodies were used: CD14 and anti-CD45 (BD Biosciences) anti CD-31,
anti-CD90 and anti-CD144 (BD Pharmigen), anti-CD34, anti CD73, anti-CD105, anti-
CD133, anti-CD146 and anti-CD309 (KDR;MiltenyiBiotec). Stained cells were acquired by a
MACSquant
1
Analyzer 10 (MiltenyiBiotec) and the multicolor analysis was performed using
FlowJo software.
Statistical Analyses
Statistical analyses were performed using the GraphPad Prism 3.0 statistical platform.
The Mann-Whitney test was used to compare the differences between preterm and term
biological samples. All differences with p<0.05 were considered statistically significant. Data
were expressed as median (range) for all the statistical analysis. Correlation analysis was per-
formed using Pearson’s Correlation r.
Results
Samples
Our study included 58 term (1 twin) and 50 preterm (11 twins) UCB samples; in the preterm
group, 21/50 neonates had a gestational age of<32 wks.
Clinical data of pre-term infants, including birth weight, gestational age, gender, clinical
problems after delivery and survival outcome are presented in Table 1. Preterm neonates had a
lower number of white blood cells (WBCx103/μL): median 4.7 (2.2–7.5) vs 8.3 (5.0–15.5)
(p = 0.0005) in comparison to full term.
CD34
We assessed whether preterm UCB leads to changes in the proportion of circulating total
CD34+ cells. The percentage of total CD34+ cells inversely correlated with the gestational age:
0.61% (range 0.15–4.8) in preterm infants (n = 50) and 0.3% (0.032–2.23) in full term (n = 57)
p = 0.0001as well as in neonates<32 weeks of gestational age compared to those having 32–36
wks GA: 0.95% (range 0.18–4.8) and 0.36% (0.15–3.2) respectively p = 0.0015. Similarly, the
number of CD34+ CD71+ cells resulted higher in preterm UCB (n = 30) with respect to term
Hematopoietic Progenitors in Pre-Term Neonates
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ones (n = 37): 24.35% (7.8–42.9) vs 14.5% (1.5–51.2) p = 0.021 but no differences were detect-
able in very preterm compared with samples from neonates between 32 and 36 wks of gesta-
tional age. (Fig 1) Different subpopulations were studied to establish the proportion of more
immature progenitors within CD34+ compartment: no difference was found in the percentage
of CD34+ CD90+ CD45RA-, but CD34+ CD38- and CD34+CD 45-cells resulted more repre-
sented in samples from pre-term cord blood than in full term (Table 2). Finally, the ALDH
activity and the expression of stemness genes like Nestin, Nanog and Oct3/4 did not differed in
CD34+ cells from term and preterm samples.(S1 Fig).
Side population
Preterm (n = 5 samples) and term (n = 5 samples) cord blood were tested for SP cells. No dif-
ferences were found between the two groups: median 1.9 (range 1.15–9.6) and median 4.3
(range 0.52–16.9)(p = 0.78). Conversely a significant difference was observed in the distribu-
tion of CD34-/CD34+ cellswithin SP: in fact preterm SP showed higher percentage of CD34-
cells compared to term SP: median 45.9 range28.8–59.0 vs median 18.8 range 10.2–24.6
(Mann-Whitney test p = 0.03). (Fig 2)
Table 1. Clinical data of preterm neonates.
Group (GA
wks)
BW (gr) GA
(wks)
Gender
(M/F)
Twins
(N)
Delivery Caesarean
/Vaginal
RDS
(%)
Survival
(%)
Cause of death (N) EOS
(%)
< 32
(n = 21)
1120 (600–
1915)
28 (22–
31)
15/6 3 19/2 95.2 90.5 Thyroid tumor (1)
Oligohydramnios (1)
14.3
>32(n = 29) 2085 (1370–
3180)
34(32–
36)
17/12 8 (1
triplet)
22/7 58.6 100 0
n = number of cord blood samples; GA,gestational age; BW, body weight; EOS,early onset sepsis; RDS, neonatal respiratory distress Syndrome; wks,
weeks. Values are represented as median (range).
doi:10.1371/journal.pone.0138680.t001
Fig 1. Frequency of circulating CD34+ cells in UCB. Four groups are considered based on gestational age (GA) of the neonates. (A) Percentage of total
CD34+ cells. (B) Percentage of CD34+CD71+. *P<0.05; **P<0.01; ****P<0.0001
doi:10.1371/journal.pone.0138680.g001
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Colony number
The absolute number of total CFCs /10μLWCB as well asthe frequency of CFC/5x104NC obser-
vedin the second generationresulted higher in preterm samples compared to term ones
(p = 0.004 and p = 0.05 respectively; Table 3). In addition,the CFCs number /10μLWCBresulted
inversely correlated with the gestational age of the neonates (Pearson r = -0.3001 p = 0.0168),
although the number of cells for each colony was not affected by gestational age (p = 0.9).
All lineages were represented in culture with a prevalence of erythroid colonies (BFU-E) in
the first and in the second generation (Table 3). The re-plating efficiency of term CB resulted
lower compared to preterm (68% vs 82% in secondary generation) and only pre-term samples
(17%) could grow until the third generation.
Table 2. Different CD34+ subpopulation in preterm and term cord blood.
CD34 Subpopulation (%) Preterm (n = 6) Term (n = 6) aP-value
CD34+CD38- 65.1 (37.1–84.3) 31.1 (8.9–35.3) <0.001
CD34+CD45- 0.12 (0.09–0.14) 0.02 (0.00–0.04) 0.041
CD34+CD90+/CD45RA- 1.54 (1.05–3.21) 2.19 (0.52–14.50) 0.309
n. = number of cord blood samples Values are represented as median (range)
ap values were calculated using Mann-Whitney t test.
doi:10.1371/journal.pone.0138680.t002
Fig 2. Side population (SP) analysis of humanmononuclear cells obtained from pre-term and term cord blood. (A) DyeCycle Violet (DCV) blue vs red
fluorescence is shown for all cells within the viable (7AAD-) CD45+dim/SCC low gate of the scatter plot. In these representative samples, 1.93% (for pre-
term: GA<37 wks) and 4.31% (for term: GA37 wks) of the cells fall within the gated SP (-Verapamil) and are sensitive to Verapamil (+ Verapamil). (B)
Expression of CD34 and CD338 (ABCG2 transporter) within SP population of preterm (n = 5) and term (n = 5) cord blood.
doi:10.1371/journal.pone.0138680.g002
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In this contest, we have analyzed the percentage of CD34+ cells in colonies grown in semi-
solid medium. No difference was observed between term and preterm UCB in the percentage of
CD34+ cells in the first generation: median 5.28% (3.58–5.29) vs 3.05% (1.15–5.2) p = 0.17; con-
versely in the second generation, the median percentage of CD34+ resulted significantly higher
in preterm colonies vs term: 8.39 (5.0–10.5) and 0.82 (0.32–3.0) respectively (p = 0.0017).
Endothelial cells
Colonies of endothelial cells (ECFCs) typically appeared between day +5 and day +14 and were
identified as well-circumscribed monolayers of cobblestone-appearing cells which enlarged
rapidly. These cells omogenously expressed CD31 antigen. A time-course picture of living
ECFCs are show in Fig 3.
Table 3. Clonogenic growth efficiency in preterm and term infants.
GENERATION
FIRST SECOND THIRD
Group Cell number per
colony/x105NC
CFC/
10microLWCB
BFU-E/
10microL WCB
CD34+
(%)
Group CFC/
5x104 NC
BFU-E/
5x104 NC
CD34+
(%)
CFC/
105NC
Preterm
(n = 33)
1.1 (0.39–1.92) 68 (36–138) 28 (10–60) 3.1 (1.2–
5.2)
Preterm
(n = 14)
21 (0–88) 18 (0–86) 8.4 (5.0–
10.5)
2 (0–3)
Term
(n = 35)
1.0 (0.4–2.1) 60 (8–84) 30 (2–62) 5.3 (3.6–
5.3)
Term
(n = 16)
5 (0–75) 3 (0–32) 0.8 (0.3–
3.0)
0
aP-value 0.9 0.004 0.9 0.17 aP-value 0.05 0.002 0.0017
n = number of samples; CFC,Colony forming cells; BFU-E, burst forming units of the erythroid lineage; NC, nucleated cells. Values are represented as
median (range). ﬁrst generation = colonies grown from whole cord blood (1); second generation = colonies grown from cells harvested pooling ﬁrst
generation colonies(2); third generation = colonies grown from (2)
ap values were calculated using Mann-Whitney t test;
doi:10.1371/journal.pone.0138680.t003
Fig 3. Endothelial Colony Forming Cell (ECFC) in pre-term and term- umbilical cord blood. Representative photomicrographs of ECFCs from
mononuclear cells isolated from pre-term (GA<37 wks, A-C) and term (GA37 wks, E-G) cord blood at different time of culture (Original magnification 50X).
(D,H) Immunofluorescence staining of CD31 (green) and DAPI (blue) (Original magnification 200X).
doi:10.1371/journal.pone.0138680.g003
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ECFCs showed in vitro a variable capacity to grow (11% UCB samples of both groups did
not grow endothelial cells). The median frequency of ECFCs in cord blood samples of term
and preterm neonates was7.8 /107 MNC (range = 0–21.4) and 5.4 /107(range 0–55.0), respec-
tively (p = 0.5). This frequency does not correlate with the gestational age nor with other
maternal (hypertension, antenatal steroid exposure, multiple pregnancy) or neonatal charac-
teristics (sex, RDS, intubation, early-onset sepsis).
Endothelial progenitors gave rise to large colonies (median 2.0 x104 nucleated cells/colony;
range 0.3–6.1x104) and expanded rapidly in culture: a median of 3.0 fold expansion in the
number of endothelial cells from the first to the second generation (range 1.3–10.4) and a
median of 2.6 fold expansion from the second to the third (range 0.9–8.4). No differences were
observed between preterm and full-term CB (data not shown). ECFCs expressed typical endo-
thelial markers (CD31, CD144, CD146) and CD73 (Table 4).
CD34 antigen was present in the majority of the endothelial cells (> 75%) expanded in vitro
and showed a range of expression from bright to dim both in preterm and term samples. A
small percentage of CD34+KDR+ cells were also represented in ECFCs from both preterm and
full term CB (Table 5).
TaqMan1Gene Expression Assays
We have analyzed the expression of several genes, mainly related to stemness maintenance and
cell differentiation in selected CD34+ cells (S1 Table). Overall, the pattern of expression did
not significantly differed between the two groups. Only a few genes were not expressed in full-
term CD34+ cells respect to preterm: NFIL3, ETS1, SET, PRDM1, and ID2. Several genes
resulted differently over-expressed (as genes involved in the maintenance of self-renewal, stem
cell reprogramming and pluripotency as well as genes essential in regulating the development
and maintenance of hematopoiesis) in full term and in preterm progenitors but comparison
between the two groups failed to identify statistically significant differences (S2 Fig).
Discussion
In this study, we show that the proportion of total CD34+ cells in the cord blood of preterm
neonates is higher compared to full term neonates and this difference is inversely correlated
with gestational age: in fact, the highest proportion of CD34+ cells is found in samples from
Table 4. Analysis of the cell surface antigens of cord blood ECFCs from preterm and term neonates.
Cell surface antigen Preterm (n = 12) Term (n = 12)
CD45 <10.0 <0.5
CD14 <1.0 <0.5
CD31 >95.0 >95.0
CD144 >95.0 >96.2
CD309 >29.4 >25.9
CD146 >94.9 >99.0
CD73 >98.7 >89.62
CD105 >99.0 >99.67
CD117 >50.0 >49.5
CD133 >32.3 >19.5
n. = number of samples evaluated.
Values are represented as percentage (%) of positive cells.
doi:10.1371/journal.pone.0138680.t004
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very immature babies (<32GA).There are additional evidences for the presence of a more
immature progenitor in the preterm UCB compared to term: a) higher percentage of cells with
the phenotype of immature HP (CD34+/CD38-);b) higher absolute number of CFCs; c) capac-
ity to grow colony in vitro until the third generation; d) the significant inverse correlation
between the absolute number of colony and the gestational age; e) higher proportion of CD34+
cells harvested from the second generation of colonies. All these features are paralleled by over-
expression of genes involved in the maintenance of self-renewal (ID2, SET, TBPL1)[25–27]
and genes related to the expansion of the hematopoietic stem cell pool (HOXB3, DPPA4) [28,
29].
We found that the majority of CD34+ cells co-express CD71 antigen (p<0.05 term vs pre-
term); this translate in a prevalent growth in vitro of large bursts [30]. Interestingly, in the sec-
ond generation the vast majority of the colonies are erythroid. The prevalence of the erythroid
lineage commitment within the CD34+ cell population and the capacity of these progenitors to
growin secondary generation, is suggestive for the presence in cord blood of an immature pro-
genitor devoid to transport oxygen, carbon dioxide and to facilitate vascular remodeling. These
progenitor cells disappear very soon after birth[31, 8].
UCB from full term newborns exhibit a higher WBC count than UCB from preterm, but a
lower HP concentration in keeping with a previous study [11].This difference is inversely cor-
related with the gestational age, thus suggesting that circulating CD34+ cells do not substan-
tially expand from the second to the third trimester of the fetal life or that this population
undergoes expansion but leaves the circulation and progressively reaches the hematopoietic
niches in the bone marrow. In fact, it has been demonstrated in the humans, that the vascular
microenvironment reaches relative maturity by 20th gestational week and that osteoblastic/
endosteal niche is completed later, when mesenchymal (endochondral) tissue became ossified
[8]. Thus, it is possible that, a population of immature HP can persist into the blood stream of
the preterm neonates before homing into a transient endothelial niche and finally into the tra-
becular bone, as demonstrated in the zebrafish model [32].
In our analysis, endothelial progenitor cells frequency (measured as ECFC) present in the
cord blood did not show to be correlated with gestational age nor with maternal or neonatal
characteristics. These data differ from other studies [18] which suggest that circulating endo-
thelial progenitors are correlated with Bronchopulmonary Dysplasia (BPD) occurrence in pre-
term infants. These differences may be explained by the assay used: our data are based on
functional studies and not on phenotypic analyses of whole cord blood.
ECFC grew in vitro large number of endothelial cells until the third generation that strongly
expressed CD73, an ecto-5’-nucleotidase that convert adenosine triphosphate to adenosine, as
well as CD31, CD34 and CD146, thus resembling a transitional phenotype between mesenchy-
mal stem cells and endothelial progenitors. Usually, Endothelial-Mesenchymal Transition
Table 5. Different CD34+ subpopulation in endothelial progenitors.
CD34 Subpopulation Preterm (n = 5) Term (n = 5) aP-value
CD34bright 31 (24–60) 12.7 (2.1–58.2) NS
CD34dim 65 (45–71) 60.7 (46.5–81.2) NS
34+ tot. 73.4 (36–89.9) 85.2 (52–97) NS
34+KDR+ 8.1 (6.0–18.0) 6.74 (1.2–26.3) NS
n. = number of samples evaluated; NS = not statistically signiﬁcant. Values are represented as median
(range).
ap values were calculated usingMann-Whitney t test
doi:10.1371/journal.pone.0138680.t005
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(EndMT) is considered a source for fibroblasts and myofibroblasts for cardiac development as
well as, a pathologic condition occurring during tumor development and organ fibrosis. How-
ever, recent studies have found that EndMT cells also had ‘stemness’, which means they could
differentiate into cells of multiple lineages [33]. In this contest, endothelial progenitors isolated
and expanded in vitro from UCB, probably identify a populations of progenitors with high pro-
liferative potential, immature phenotype (CD34+ KDR+CD45-) and capable to differentiate
toward endothelial cells, smooth muscle cells and fibroblasts [34].
Cell therapy is a promising opportunity of regenerative medicine that can be used to treat
some complications related to prematurity as respiratory distress, neurological, gastrointestinal
and ophthalmological diseases [17]. However, the therapeutic use of preterm cord blood has
some limits: the first one is that it is considered “not elegible for donation” due to the scarce
number of cells except in the autologous setting [35]. The second is that preterm CD34+ cells
show impaired homing ability, at least in the NOD/SCID mouse model [14]; these data do not
still exclude that the re-infusion of hemopoietic progenitors with high proliferative potential,
although not supporting a stable engraftment, may reduce the number of red cell transfusions
in preterm babies [36].In addition, as in the paper [14] mice were transplanted using enriched
CD34+ cells, it may be possible the fraction CD34- of the SP can have a role to ameliorate the
hematological parameters.
Finally, the presence, in the cord blood of preterm babies, of endothelial/mesenchymal stem
cells with high proliferative potential makes this tissue an important autologous source of cells
capable to migrate to the site of inflammation for healing damage tissues [37] or to produce
microvesicles which can protect organs from oxidative stress [38].
However, pre-clinical studies should clarify which therapeutic strategy may be more benefi-
cial to prevent complications related to preterm birth: whether to infuse autologous fresh cord
blood cells soon after delivery or to isolate and expand in vitro specific progenitor cells (HSC
and/or endothelial) and re-infuse them at later time.
Supporting Information
S1 Fig. Expression of pluripotency genes and ALDH functional activity in cord blood
CD34+ cells from preterm and term neonates. (A) A representative flow cytometric analysis
of Nestin, OCT3/4, and NANOG expression by CD34+ cells from preterm (GA<37 wks) and
term neonates (GA37 wks). The gated area represents the CD34+ cells among CB MNC. The
black peak denotes isotype control. (B) ALDH expression in CB MNC. Gated ALDH+ cells
(left panel) were evaluated for coexpression of CD34 and CD38 (right panel). One of 4 repre-
sentative sample is shown.
(TIF)
S2 Fig. Gene expression in cord blood CD34+ cells from preterm and term infants. CD34+
cells were purified from preterm (red bars) and term (blu bars) cord blood (CB). cDNA was
prepared from total RNA and analysed as described in Materials and Methods. (A) Expression
of gene found to be down-regulated in both preterm and term CB. (B) Quantitation of gene
involved in self-renewal, stem cell reprogramming and pluripotency. (C) Quantitative analysis
of genes related to maturation and commitment of T and B lineages (D) Quantitation of gene
essential in regulating the development and maintenance of hematopoiesis and endothelial/
hemopoietic transition. Fold change of mRNA expression by CD34+ cells purified from pre-
term was calculated by normalizing to the level of calibrator gene. The evaluation included
n = 3 samples from both preterm and term CD34+ cells. sample was analysed in duplicate and
contained a pool of CD34isolated from 2 to 4 CB from each group.
(TIF)
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S1 Table. List of target genes evaluated in CD34+ cells isolated from preterm and term cord
blood.
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